• Dr Richard Mead
    Dr Richard Mead PhD

    Richard Mead is a Senior Lecturer (associate professor) at the Sheffield Institute for Translational Neuroscience. He has 16 years’ experience in preclinical drug discovery in academia and industry and has a track record of taking compounds through preclinical programs to nomination for clinical development. He has worked on the target pathway (NRF2-KEAP1) for over 8 years and taken a reactive Nrf2 activator from screening to orphan designation with the EMA for MND. He is a named inventor on 4 patents and has attracted funding of £7.4M as primary investigator and co-investigator.

  • Ross McMaster
    Ross McMaster FCCA (Company Secretary)

    Ross McMaster is financial consultant at Sheffield University Enterprises Ltd (Suel). A Fellow of the Association of Chartered Certified Accountants with a BA [Hons] in Accounting and Business, Ross specialises in the provision of management accounting services, strategic and business planning, financial forecasting and statutory accounts preparation for SMEs.

    During his time at Suel, Ross has been involved in a variety of fundraising transactions for private limited companies. He also provides corporate governance guidance whilst holding the position of company secretary to a number of companies spun out from the University of Sheffield.

  • Steve Ford
    Steve Ford

    Steve Ford is currently the chief executive of Parkinson’s UK following a career as general manager and chief executive in the NHS. Under his leadership, PUK have made significant progress towards their vision to find a cure and improve life for everyone affected by Parkinson’s. He was named Charity Leader of the Year in 2016.

  • Arthur Roach
    Arthur Roach PhD

    Arthur Roach is Director of Research at Parkinson’s UK. Before joining Parkinson’s UK Arthur held several academic and industrial positions, most recently as Senior Director, Neurodegenerative Diseases Research at Merck Serono. He is also a founder and Head of the SAB of the Swiss-based biotech Chord Therapeutics.